Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy
A Phase I Study of Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
This PHASE1 trial investigates Hodgkin Lymphoma and Lymphocytic Leukemia and is currently completed. H. Lee Moffitt Cancer Center and Research Institute leads this study, which shows 16 recorded versions since 2021 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
16 versions recorded-
Jan 2026 — Present [monthly]
Completed PHASE1
-
Sep 2025 — Jan 2026 [monthly]
Completed PHASE1
-
Jun 2025 — Sep 2025 [monthly]
Completed PHASE1
-
Apr 2025 — Jun 2025 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Mar 2025 — Apr 2025 [monthly]
Active Not Recruiting PHASE1
▶ Show 11 earlier versions
-
Jan 2025 — Mar 2025 [monthly]
Active Not Recruiting PHASE1
-
Sep 2024 — Jan 2025 [monthly]
Active Not Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE1
-
May 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE1
-
Apr 2024 — May 2024 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Nov 2023 — Apr 2024 [monthly]
Recruiting PHASE1
-
Jul 2023 — Nov 2023 [monthly]
Recruiting PHASE1
-
Feb 2023 — Jul 2023 [monthly]
Recruiting PHASE1
-
Sep 2022 — Feb 2023 [monthly]
Recruiting PHASE1
-
Apr 2022 — Sep 2022 [monthly]
Recruiting PHASE1
-
Nov 2021 — Apr 2022 [monthly]
Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- H. Lee Moffitt Cancer Center and Research Institute
- Secura Bio, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .